NUCB2 and glioblastoma: Consistently, TISIDB analysis revealed robust positive correlations between NUCB2 expression and several immunoinhibitory molecules in GBM samples (n = 166), including IL10RB (ρ = 0.455, p = 1.1e‐09; Figure 4E), PDCD1LG2 (ρ = 0.277, p = 0.000325; Figure 4F), IL10 (ρ = 0.223, p = 0.00403; Figure 4G), IDO1 (ρ = 0.267, p = 0.000532; Figure 4H) and CD96 (ρ = 0.252, p = 0.00111; Figure 4I).